In a large population-based cohort study, conventional depot antipsychotics turned out to be superior to risperidone long-acting injection, Danish researchers reported here at the New Clinical Drug Evaluation Unit (NCDEU) 51st Annual Meeting, sponsored by the American Society of Clinical Psychopharmacology.
“Newer does not necessarily mean better,” Jimmi Nielsen, MD, PhD, from Aalborg Psychiatric Hospital, Aalborg, Denmark, told Medscape Medical News.
“People tend to think that new equals improved, but as we found, the conventional depot antipsychotic formulation was more effective and it also was much cheaper.”
Risperidone long-acting injection (RLAI), the first atypical depot antipsychotic, is widely used in Europe and the United States, and its superiority to placebo and oral antipsychotics has been shown in several randomized controlled trials, Dr. Nielsen said.
“Only a few studies have compared RLAI with the conventional depot formulation, so we decided to look at this issue in a large population using our Danish nationwide registers,” he said.
By Fran Lowry